AZN ASTRAZENECA PLC
Price Chart
Executive Summary
AstraZeneca reported strong Q1 2026 results with Total Revenue up 8% CER to $15.3B, driven by Oncology (+16% CER) and Rare Disease (+15% CER). Core EPS grew 5% CER to $2.58, and FY 2026 guidance for mid-to-high single-digit revenue growth and low double-digit Core EPS growth was reaffirmed. The company also closed a $1.2B upfront collaboration with CSPC for obesity/diabetes therapies and reported positive Phase III readouts for tozorakimab and efzimfotase alfa.
Actionable Insight
Solid earnings beat with broad-based growth in Oncology and Rare Disease offsets CVRM weakness. The CSPC obesity deal adds long-term pipeline optionality but near-term R&D spend will increase. Guidance reaffirmation supports current valuation. Watch for H1 2026 results on 27 July 2026 and upcoming Phase III readouts for Enhertu (DESTINY-Breast05) and Calquence (AMPLIFY).
Key Facts
- Total Revenue $15,288M, up 8% CER (actual +13%)
- Reported EPS $1.99, up 8% CER; Core EPS $2.58, up 5% CER
- Oncology revenue +16% CER, Rare Disease +15% CER
- CVRM revenue declined 6% CER, primarily due to Farxiga generic competition
- FY 2026 guidance reaffirmed: mid-to-high single-digit revenue growth, low double-digit Core EPS growth
- Closed $1.2B upfront collaboration with CSPC for obesity/type 2 diabetes therapies
- Positive Phase III data for tozorakimab (COPD) and efzimfotase alfa (HPP); Enhertu patent litigation resolved favorably
- Net debt increased to $25.9B, driven by financing activities and business development payments
Financial Impact
Q1 2026 revenue $15.3B, operating profit $4.2B (reported) and $5.4B (core); Core EPS $2.58, up 5% CER; $1.2B upfront for CSPC deal and $100M for Jacobio
Risk Factors
- Generic competition pressuring CVRM revenue, especially Farxiga and Brilinta
- Increased leverage from $1.2B CSPC upfront and $1.99B new debt issuance
- Litigation overhang from 340B antitrust appeal and Texas qui tam trial scheduled for August 2026
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-004047 |
| Document: 0001654954-26-004047-index-headers.html | 0001654954-26-004047 |
| Document: 0001654954-26-004047-index.html | 0001654954-26-004047 |
| Document: 0001654954-26-004047.txt | 0001654954-26-004047 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
8d ago
|
6-K
| $179.55 $185.95 | ▲ +3.57% | ▲ +6.32% | $181.55 (+1.12%) |
|
Jun 1, 2026
8d ago
|
6-K
| $179.55 $185.95 | ▲ +3.57% | ▲ +6.32% | $181.55 (+1.12%) |
|
May 29, 2026
11d ago
|
6-K
| $185.49 $185.93 | ▲ +0.24% | ▲ +2.76% | $181.55 (−2.12%) |
|
May 28, 2026
12d ago
|
25-NSE
| $185.34 $181.75 | ▼ −1.94% | ▼ −2.25% | $181.55 (−2.04%) |
|
May 27, 2026
13d ago
|
6-K
| $185.62 $176.10 | ▼ −5.13% | ▼ −5.60% | $181.55 (−2.19%) |
|
May 27, 2026
14d ago
|
Court Ruling
| $185.62 $177.45 | ▼ −4.40% | ▼ −5.61% | $181.55 (−2.19%) |
|
May 26, 2026
14d ago
|
6-K
| $187.11 $177.39 | ▼ −5.19% | ▼ −6.41% | $181.55 (−2.97%) |
|
May 26, 2026
14d ago
|
6-K
| $187.11 $177.39 | ▼ −5.19% | ▼ −6.41% | $181.55 (−2.97%) |
|
May 18, 2026
22d ago
|
6-K
| $183.91 $187.11 | ▲ +1.74% | ▲ +0.12% | $181.55 (−1.28%) |
|
May 18, 2026
22d ago
|
6-K
| $183.91 $187.11 | ▲ +1.74% | ▲ +0.12% | $181.55 (−1.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access